Literature DB >> 8375112

Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants.

M G Rizzo1, S Soddu, G Tibursi, B Calabretta, A Sacchi.   

Abstract

The structure and the function of the p53 gene were studied in two metastatic cell variants derived from Lewis lung carcinoma. Single missense mutation at codon 334 was detected in the p53 gene of both cell variants. In spite of the identical mutation, the in vitro and in vivo growth rates of the two cell variants were differentially affected by the constitutive expression of exogenous wild-type (wt) p53 gene. In fact, only the more malignant cell line (C87) was severely affected by the wt-p53 gene introduction. However, the in vivo effects on this cell line were transient because during serial in vivo passages, cell populations lacking the wt-p53 gene were selected. Genetic mechanisms responsible for the resistance of the less metastatic cell variant (BC215) to the wt-p53 expression, were investigated. Intrinsic ability to mutate exogenous cDNA sequences was tested. We report that BC215 cells continued to express exogenous wt-p53 sequences after several in vitro passages. The expression of mdm2 gene was evaluated. The data demonstrated that BC215 cells constitutively express higher levels of mdm2 gene than C87 cells. We conclude that the overexpression of this gene might be responsible for the resistance of BC215 cells to exogenous wt-p53 gene expression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375112     DOI: 10.1007/bf00132980

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

3.  Allele loss on short arm of chromosome 17 in breast cancers.

Authors:  J Mackay; C M Steel; P A Elder; A P Forrest; H J Evans
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

4.  Immunologically distinct p53 molecules generated by alternative splicing.

Authors:  N Arai; D Nomura; K Yokota; D Wolf; E Brill; O Shohat; V Rotter
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate.

Authors:  Y M Chen; P L Chen; N Arnaiz; D Goodrich; W H Lee
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

9.  High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.

Authors:  D D'Amico; D Carbone; T Mitsudomi; M Nau; J Fedorko; E Russell; B Johnson; D Buchhagen; S Bodner; R Phelps
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

10.  Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.

Authors:  R Zakut-Houri; B Bienz-Tadmor; D Givol; M Oren
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

View more
  4 in total

1.  Targeting p53-dependent stem cell loss for intestinal chemoprotection.

Authors:  Brian J Leibowitz; Liheng Yang; Liang Wei; Monica E Buchanan; Madani Rachid; Robert A Parise; Jan H Beumer; Julie L Eiseman; Robert E Schoen; Lin Zhang; Jian Yu
Journal:  Sci Transl Med       Date:  2018-02-07       Impact factor: 17.956

2.  Retinoic acid negatively regulates beta 4 integrin expression and suppresses the malignant phenotype in a Lewis lung carcinoma cell line.

Authors:  C Gaetano; A Melchiori; A Albini; R Benelli; R Falcioni; A Modesti; A Modica; S Scarpa; A Sacchi
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

3.  The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.

Authors:  Alexander H Staudacher; Fares Al-Ejeh; Cara K Fraser; Jocelyn M Darby; David M Roder; Andrew Ruszkiewicz; Jim Manavis; Michael P Brown
Journal:  EJNMMI Res       Date:  2014-01-04       Impact factor: 3.138

4.  Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors.

Authors:  Yafeng Wang; Guiquan Zhang; Qingzhou Meng; Shisheng Huang; Panpan Guo; Qibin Leng; Lingyun Sun; Geng Liu; Xingxu Huang; Jianghuai Liu
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.